HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $190
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $160 to $190.
August 05, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Neurocrine Biosciences and raised the price target from $160 to $190.
The raised price target from $160 to $190 by HC Wainwright & Co. indicates increased confidence in Neurocrine Biosciences' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100